By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ChromaDex, Inc. 

10005 Muirlands Boulevard
Suite G, First Floor
Irvine  California  92618  U.S.A.
Phone: 949-419-0288 Fax: 949-419-0294



Company News
ChromaDex, Inc. To Present At 27th Annual Piper Jaffray Healthcare Conference 11/24/2015 10:37:30 AM
Jarrow Formulas Plans U.S. Retail Launch Of A Nicotinamide Riboside Product Featuring ChromaDex, Inc.’s NIAGEN 11/23/2015 10:16:32 AM
NIH And ChromaDex, Inc. Announce Material Cooperative Research And Development Agreement To Study The Effects Of Chromadex’s NIAGEN Nicotinamide Riboside On Cockayne Syndrome And Ataxia Telangiectasia 11/18/2015 7:21:41 AM
ChromaDex, Inc. Lead Ingredient NIAGEN Nicotinamide Riboside Receives New Dietary Ingredient (NDI) Status From The FDA 11/16/2015 10:39:47 AM
ChromaDex, Inc. Announces $2,000,000 Registered Direct Offering 11/5/2015 12:43:08 PM
ChromaDex, Inc. Enters Into An Exclusive Joint Development Agreement With The Procter & Gamble (PG) 11/5/2015 10:33:20 AM
ChromaDex, Inc. Presentation Now Available For On-Demand Viewing 10/8/2015 9:56:19 AM
ChromaDex, Inc. To Webcast, Live, At October 1 9/28/2015 12:28:01 PM
Results From First Human Clinical Study Demonstrate ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Effectively Increases The Co-Enzyme NAD+ And Is Safe 8/12/2015 10:35:48 AM
ChromaDex, Inc. Announces A Collaborative Human Clinical Study On NIAGEN With The University of Colorado Boulder 6/18/2015 7:49:46 AM